Rapid weight loss, a common outcome with GLP-1 drugs, can trigger telogen effluvium, causing more hair follicles to enter the resting phase where shedding occurs
Weight loss goals (targets and expectations) Semaglutide use has resulted in significant weight loss in the treatment of T2DM and obesity
Metabolic benefits extend beyond weight loss, including improved insulin sensitivity, better lipid profiles, reduced inflammatory markers, and potential cardiovascular protection
[11] [4] Preclinical studies have suggested that combining amylin receptor agonism with GLP-1based therapies produces greater reductions in food intake and body weight than either approach in isolation, and early clinical data from the CagriSema programme (cagrilintide combined with semaglutide) has provided some supporting evidence in humans
A type of glial cells called astrocytes seem to also use fatty acids for energy production [32,33]
Typical timeline During the first two to four weeks on the starting dose of 2.5 mg, most patients lose 2 to 5 pounds